Soft Tissue Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3495
Buy Report Download FREE Resources

Published: June 26, 2024 Report Code: GDHC158CL-ST

Select Item

Soft Tissue Sarcoma (STS) Marketed and Pipeline Drugs Report Overview

Soft tissue sarcoma (STS) encompasses more than 50 types of cancer that develop in the body’s soft tissues, which include muscles, fat, and nerves. These tumors primarily occur in areas like the arms, legs, chest, or abdomen. Soft tissue sarcomas exhibit diverse subtypes, each displaying unique traits and behaviors. They can differ in terms of aggressiveness, rate of growth, and propensity to metastasize to distant organs. In 2024, 368,024 diagnosed prevalent cases of STS are anticipated in 16 countries. In 2024, China is expected to report the highest number of prevalent cases of STS, followed by India.

The STS marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for STS. The report also provides actionable insights into the clinical and commercial landscapes of STS drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.

Key Mechanisms of Action (Marketed Drugs) ·       Enzyme Inhibitor

·       Protein and Peptide Inhibitor

·       Genes, Nucleic Acids & Related Components Inhibitor

·       Receptor Inhibitor

·       Receptor Agonist
Key Molecule Type (Marketed Drugs) ·       Small Molecule

·       Biologic
Key Mechanisms of Action (Pipeline) ·       Enzyme Inhibitor

·       Protein and Peptide Inhibitor

·       Receptor Antagonist

·       Receptor Inhibitor

·       Receptor Agonist
Key Molecule Types (Pipeline) ·       Biologic

·       Small Molecules

·       Oligonucleotide
Top Players ·       Roche

·       BMS

·       Novartis

·       Boehringer Ingelheim

·       Epizyme

·       Key Oncologics
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

STS Marketed Drugs Market Segmentation by Mechanisms of Action

The key MoA of the marketed drugs in the STS pipeline mainly includes enzyme inhibitor, protein and peptide inhibitor, genes, nucleic acids & related components inhibitor; receptor inhibitor, receptor agonist among others. Most of the drugs followed enzyme inhibitor MoA in 2024 in the STS market.

Soft tissue sarcoma Marketed Drugs Market Analysis by Mechanisms of Action, 2024 (%)

Soft tissue sarcoma Marketed Drugs Market Analysis by Mechanisms of Action, 2024 (%)

Buy the Full Report to Know More about the MoA of STS Marketed Drugs

Download a Free Report Sample

STS Marketed Drugs Market Segmentation by Molecule Types

In 2024, the leading molecule type for STS marketed drugs was small molecule, followed by biologic.

Soft tissue sarcoma Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)

Soft tissue sarcoma Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)

Buy the Full Report to Know More about the Molecule Types of STS Marketed Drugs

Download a Free Report Sample

STS Pipeline Drugs Market Segmentation by Mechanisms of Action

The key MoA of the pipeline drugs in the STS market mainly includes enzyme inhibitor, protein and peptide inhibitor, receptor antagonist, receptor inhibitor, and receptor agonist among others. Most of the drugs followed enzyme inhibitor MoA in 2024 in the development of STS pipeline drugs.

STS Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)

STS Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)Buy the Full Report to Know More about the MoA of STS Pipeline Drugs

Download a Free Report Sample

STS Pipeline Drugs Market Segmentation by Molecule Types

In 2024, the leading molecule type for STS pipeline drugs was biologic. It was followed by small molecules and oligonucleotide.

STS Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)

STS Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)

Buy the Full Report to Know More about the Molecule Types of STS Pipeline Drugs

Download a Free Report Sample

STS Marketed and Pipeline Drugs Market – Commercial Assessment

The current innovation landscape of treating STS is fiercely competitive, with the active engagement of big pharma giants like Roche, Novartis, BMS, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical/Advenchen Laboratories, Epizyme and Key Oncologics among others. The STS treatment market is expected to expand, propelled by the increasing worldwide incidence of inherited syndromes, which lead to genetic alterations affecting the genes regulating cell growth—a primary driver of the STS market.

STS Marketed and Pipeline Drugs Market Analysis by Key Players
STS Marketed and Pipeline Drugs Market Analysis by Key PlayersBuy the Full Report for More Insights into the STS Marketed and Pipeline Drugs Market Players
Download a Free Report Sample

Segments Covered in the Report

STS Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2024)

  • Receptor Agonist
  • Genes, Nucleic Acids & Related Components Inhibitor
  • Enzyme Inhibitor
  • Protein and Peptide Inhibitor
  • Receptor Inhibitor

STS Marketed Drugs Molecule Type Outlook (Number of Drugs, 2024)

  • Small Molecule
  • Biologic

STS Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2024)

  • Enzyme Inhibitor
  • Protein and Peptide Inhibitor
  • Receptor Antagonist
  • Receptor Inhibitor
  • Receptor Agonist

STS Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2024)

  • Biologic
  • Small Molecule
  • Oligonucleotide

Scope

The key components of the report include:

  • Disease Landscape

  • Disease Overview

  • Epidemiology Overview

  • Treatment Overview

  • Marketed Products Assessment

  • Breakdown by Mechanism of Action, Route of Administration

  • Product Profiles with Sales Forecast

  • Pricing and Reimbursement Assessment

  • Annual Therapy Cost

  • Time to Pricing and Time to Reimbursement

  • Pipeline Assessment

  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

  • Product Profiles with Sales Forecast

  • Late-to-mid-stage Pipeline Drugs

  • Phase Transition Success Rate and Likelihood of Approval

  • Clinical Trials Assessment

  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

  • Enrolment Analytics, Site Analytics, Feasibility Analysis

  • Deals Landscape

  • Mergers, Acquisitions, and Strategic Alliances by Region

  • Overview of Recent Deals

  • Commercial Assessment

  • Key Market Players

  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the STS market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global STS market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents (PowerPoint Deck)

1 Preface

1.1 Contents

1.2 Report Scope

1.3 List of Tables and Figures

1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview

3.2 Epidemiology Overview

3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs

4.2 Overview by Mechanism of Action

4.3 Overview by Molecule Type

4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

5.1 Annual Cost of Therapy

5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Mid-to-late-stage Pipeline Drugs

6.2 Overview by Development Stage

6.3 Overview by Mechanism of Action

6.4 Overview by Molecule Type

6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)

6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

7.1 Historical Overview

7.2 Overview by Phase

7.3 Overview by Status

7.4 Overview by Phase for Ongoing and Planned Trials

7.5 Trials with Virtual Components

7.6 Overview of Trials by Geography

7.7 Single-Country and Multinational Trials by Region

7.8 Top 20 Sponsors with Breakdown by Phase

7.9 Top 20 Sponsors with Breakdown by Status

7.10 Overview by Endpoint Status

7.11 Overview by Race and Ethnicity

7.12 Enrollment Data

7.13 Top 20 countries for Trial Sites

7.14 Top 20 Sites Globally

7.15 Feasibility Analysis – Geographic Overview

7.16 Feasibility Analysis – Benchmark Models

8 Deals Landscape

8.1 Mergers, Acquisitions, and Strategic Alliances by Region

8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

11.1 Methodology

11.2 Methodology – Sales Forecast

11.3 Methodology – Pricing and Reimbursement

11.4 Methodology – PTSR and LoA Analysis

11.5 About the Authors

11.6 Contact Us

11.7 Disclaimer

Frequently asked questions

Soft Tissue Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape standard reports
Currency USD
$3,495

Can be used by individual purchaser only

Most Popular
$6,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$10,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Soft Tissue Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Soft Tissue Sarcoma reports
Pharmaceuticals
New
Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence
$3,450 | May 2026
Pharmaceuticals
New
Q1 2026 CRO Activity and Intel Report
$1,870 | May 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, April 2026
$2,950 | May 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Soft Tissue Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape in real time.

  • Access a live Soft Tissue Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more